The unique position of EGFR as a regulator of several key oncogenic pathways, together with the fact that EGFR is frequently expressed in colorectal cancer (CRC), has made it an excellent therapeutic target for the treatment of CRC patients. This evidence concerns the gene EGFR and colorectal cancer.